BIOVECTRA BIOVECTRA is now Agilent!

WHITE PAPER

WHITE PAPER

Challenges and Opportunities in High-Potency Pharmaceuticals Manufacturing

High-potency drugs derived from natural products command a large and growing market share in the pharmaceutical industry. In 2019, revenues at contract
development and manufacturing organizations (CDMOs) related to high-potency active pharmaceutical ingredients (HPAPIs) manufacturing were an estimated $10 billion.

Download this white paper to:

High-potency drugs derived from natural products command a large and growing market share in the pharmaceutical industry. In 2019, revenues at contract
development and manufacturing organizations (CDMOs) related to high-potency active pharmaceutical ingredients (HPAPIs) manufacturing were an estimated $10 billion.
  • Learn how the expertise of CDMOs in HPAPI manufacturing is becoming increasingly relevant
  • Why clients come to CDMOs at various stages of process design and more!

HPAPIs Angled Paper Icon

About Us

With over 50 years of experience, we are a forward-thinking, North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.

Contact Us

Toll Free: +1 (866) 883-2872
Phone: +1 (902) 566-9116
Fax: +1 (902) 628-2045

11 Aviation Avenue,
Charlottetown, PE, C1E 0A1
Map

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications